Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer

Journal of Neuro-oncology
Amélie DarlixValentina Guarneri

Abstract

Breast cancer (BC) metastatic behavior varies according to the hormone receptors (HR) and HER2 statuses. Indeed, patients with triple-negative (TN) and HER2+ tumors are at higher risk of brain metastases (BM). The objective of this multinational cohort was to evaluate BM kinetics depending on the BC subtype. We retrospectively analyzed a series of BC patients with BM diagnosed in four European institutions (1996-2016). The delay between BC and BM diagnoses (BM-free survival) according to tumor biology was estimated with the Kaplan-Meier method. A multivariate analysis was performed using the Cox proportional hazards regression model. 649 women were included: 32.0% HER2-/HR+, 24.8% TN, 22.2% HER2+/HR- and 21.0% HER2+/HR+ tumors. Median age at BM diagnosis was 56 (25-85). In univariate analysis, BM-free survival differed depending on tumor biology: HER2-/HR+ 5.3 years (95% CI 4.6-5.9), HER2+/HR+ 4.4 years (95% CI 3.4-5.2), HER2+/HR- 2.6 years (95% CI 2.2-3.1) and TN 2.2 years (95% CI 1.9-2.7) (p < 0.001). It was significantly different between HR+ and HR- tumors (5.0 vs. 2.5 years, p < 0.001), and between HER2+ and HER2- tumors (3.2 vs. 3.8 years, p = 0.039). In multivariate analysis, estrogen-receptors (ER) and progesterone-rece...Continue Reading

References

Nov 1, 1979·Cancer·A DiStefanoG R Blumenschein
Feb 22, 1990·The New England Journal of Medicine·R A PatchellB Young
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Jul 11, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K D MillerG W Sledge
Jul 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jill S Barnholtz-SloanRaymond E Sawaya
Sep 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy U LinEric P Winer
Nov 3, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K SlimaneM Spielmann
Sep 30, 2005·The American Journal of Pathology·Robert J WeilPatricia S Steeg
Apr 11, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B C PestalozziUNKNOWN International Breast Cancer Study Group (IBCSG)
Dec 29, 2006·The New England Journal of Medicine·Charles E GeyerDavid Cameron
Mar 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nancy U Lin, Eric P Winer
May 1, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B C Pestalozzi
Aug 1, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Florian HeitzAndreas du Bois
Sep 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian Leyland-Jones
Nov 26, 2009·International Journal of Radiation Oncology, Biology, Physics·Anna NiwińskaMagdalena Murawska
Nov 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shaheenah DawoodSharon H Giordano
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Olivier GraesslinNuhad K Ibrahim
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagen KenneckeKaren Gelmon
Nov 27, 2010·Neurosurgery Clinics of North America·Benjamin D FoxGanesh Rao
Jan 12, 2012·British Journal of Cancer·A BerghoffR Bartsch
Dec 12, 2012·Breast Cancer Research and Treatment·Kenneth R Hess, Francisco J Esteva
Jan 29, 2013·The Breast : Official Journal of the European Society of Mastology·Erin M OlsonNancy U Lin
Mar 17, 2017·JAMA Oncology·Allison M MartinAyal A Aizer
Jul 12, 2017·Oncology Letters·Nadja E OehrlichTjoung-Won Park-Simon

❮ Previous
Next ❯

Citations

Feb 29, 2020·Oncotarget·Lola KonialiKyriacos Kyriacou
May 29, 2020·BMC Cancer·Maria da Conceição Barros-OliveiraBenedito Borges Da Silva
Aug 11, 2018·Journal of Neuro-oncology·Nooshin Hashemi-SadraeiCandece L Gladson
Apr 15, 2019·Breast Cancer Research and Treatment·Daniel N CagneyAyal A Aizer
Jun 21, 2020·Cancer Letters·Maria V BabakIrina V Balyasnikova
Apr 4, 2021·Journal of Clinical Medicine·Renaud SabatierAnthony Goncalves

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.